Eisai Co., Ltd.

This is an early-stage safety study testing a new, encapsulated form of a cancer drug called E7389 in people with advanced solid tumors. The main goals are to find the safest highest dose and understand how the body processes the drug. The study will enroll about 140 Japanese adu…

This is an early-stage study testing a new drug called E7386 in people with advanced solid tumors that have spread or returned after previous treatments. The main goal is to find the safest dose and understand side effects in about 70 participants. Researchers will also check if …

This study is monitoring the safety of an approved lymphoma drug called tazemetostat in everyday medical practice. It involves 145 Japanese patients whose follicular lymphoma has returned or hasn't responded to previous treatments and who have a specific genetic mutation. Researc…

This study is testing a new, encapsulated form of a cancer drug (E7389-LF) given together with an existing immunotherapy drug (nivolumab) in people with advanced solid tumors. The first part aims to find a safe and tolerable dose. The second part will see how well the combination…

This early-stage study is testing the safety of an experimental drug called E7090, both alone and combined with other cancer medications. It involves 51 women with advanced, hormone-sensitive breast cancer that has returned or spread. The main goal is to find safe dosage levels a…